by Henry Maia Peixoto, Paola Barbosa Marchesini, Maria Regina Fernandes de Oliveira
Transactions of The Royal Society of Tropical Medicine and Hygiene, Vol. 110, Issue 11, Published: 01 February 2017
Due primarily to the presence of measurement bias in the selected studies, the quality of the evidence was considered predominantly moderate. Statistically significant associations were not observed when artesunate-mefloquine (ASMQ) was compared to other artemisinin-based combination therapies (ACTs). For comparisons with artesunate-amodiaquine and artesunate+sulfadoxine-pyrimethamine, the results were favourable to ASMQ. No deaths were attributed to ASMQ, severe adverse events were rare and some studies indicate a higher frequency of mild adverse events.